ZEVTERA (Ceftobiprole Medocaril Sodium) Patent Expiration, LOE Window & CMS Spending

ZEVTERA (Ceftobiprole Medocaril Sodium) by Istx: FDA Orange Book LOE 2034-04-03, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $2,350 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorIstx
FDA Application & PathwayN218275 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2034-04-03
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($2,350 intro WAC)